River BioMedics
River BioMedics is a Dutch biotech company focused on cardiac drug discovery. They develop advanced 3D human cardiac models for the discovery and development of novel cardiac drugs, combining expertise in bio-engineering, cardiac biology, and human induced pluripotent stem cells (hiPSC). The company aims to address high unmet medical needs in cardiovascular disease, especially heart failure, by providing human predictive 3D in-vitro models for target validation and drug screening.
Industries
Nr. of Employees
small (1-50)
River BioMedics
Patents
Products
3D cardiac strip platform
Engineered hiPSC-derived 3D cardiac strip tissues used to measure functional cardiac endpoints and support drug screening and target validation.
Heart-on-a-chip platform
Microfluidic organ-on-chip systems hosting human cardiac tissues to provide controlled microenvironments and enable perfusion and mechanistic assays.
Mini-heart (pumping cardiac construct)
Miniaturized pumping cardiac constructs developed to recapitulate cardiac pumping function and biomechanics for advanced functional testing.
3D cardiac strip platform
Engineered hiPSC-derived 3D cardiac strip tissues used to measure functional cardiac endpoints and support drug screening and target validation.
Heart-on-a-chip platform
Microfluidic organ-on-chip systems hosting human cardiac tissues to provide controlled microenvironments and enable perfusion and mechanistic assays.
Mini-heart (pumping cardiac construct)
Miniaturized pumping cardiac constructs developed to recapitulate cardiac pumping function and biomechanics for advanced functional testing.
Services
Discovery and preclinical development of small-molecule therapeutics for cardiac disease using in-house hiPSC-derived 3D cardiac models, functional assays and target validation workflows; engagement via partnerships and collaborative projects.
Participation and leadership in multi‑partner projects to develop advanced cardiac models (e.g., pumping mini-heart) and scale technologies through grant-funded consortia.
Discovery and preclinical development of small-molecule therapeutics for cardiac disease using in-house hiPSC-derived 3D cardiac models, functional assays and target validation workflows; engagement via partnerships and collaborative projects.
Participation and leadership in multi‑partner projects to develop advanced cardiac models (e.g., pumping mini-heart) and scale technologies through grant-funded consortia.
Expertise Areas
- Cardiac disease modelling
- hiPSC-derived cardiomyocyte differentiation and maturation
- Organ-on-chip and microfluidics
- 3D tissue engineering (cardiac strips and mini-tissues)
Key Technologies
- Human induced pluripotent stem cell (hiPSC) differentiation
- 3D cardiac tissue engineering (cardiac strips)
- Organ-on-chip microfluidic platforms
- Miniature pumping cardiac constructs (mini-heart)
News & Updates
Nicky Cooper, CEO of River BioMedics, attended the WORD+ 2025 conference in Cambridge, UK.
Celebration of five years of innovation and progress in cardiac drug discovery.
A progress report on the development of engineered living materials for biomedical applications.
Marcelo Ribeiro presented the company at the Dutch Life Science conference as part of the Health~Holland Venture Challenge.
The company received €250,000 from NWO (Dutch Research Council) to accelerate product development.
Funding to develop a pumping human Mini-heart and swimming human Bio-Robot, led by a consortium including River BioMedics.
Nicky Cooper, CEO of River BioMedics, attended the WORD+ 2025 conference in Cambridge, UK.
Celebration of five years of innovation and progress in cardiac drug discovery.
A progress report on the development of engineered living materials for biomedical applications.
Marcelo Ribeiro presented the company at the Dutch Life Science conference as part of the Health~Holland Venture Challenge.
The company received €250,000 from NWO (Dutch Research Council) to accelerate product development.
Funding to develop a pumping human Mini-heart and swimming human Bio-Robot, led by a consortium including River BioMedics.